A Long-Term Extension Study Of IMVT-1402 In Adult Participants With Graves' Disease (GD)

Overview

About this study

This is a long-term extension study that will rollover participants completing feeder studies IMVT-1402-2502 (NCT06727604) or IMVT-1402-2503 (NCT07018323) to evaluate the efficacy and safety of IMVT-1402 in adult participants with GD. Eligible participants will be assigned to 1 of 3 study groups (Groups A, B and C) based on their GD status at the completion of their respective feeder study.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

* Participants who completed Study IMVT-1402-2502 or Study IMVT-1402-2503.
* Other, more specific inclusion criteria are defined in the protocol.

Exclusion Criteria:

* Have permanently discontinued IMP during the treatment period in the feeder study or have met study stopping criteria at any point up until the end of participation in the feeder study.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 03/302026. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Marius Stan, M.D.

Open for enrollment

Contact information:

Bridgette Halder

5074222780

halder.bridgette@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20603003

Mayo Clinic Footer